BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murray GI, Patimalla S, Stewart KN, Miller ID, Heys SD. Profiling the expression of cytochrome P450 in breast cancer. Histopathology 2010;57:202-11. [PMID: 20716162 DOI: 10.1111/j.1365-2559.2010.03606.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Zia H, Murray GI, Vyhlidal CA, Leeder JS, Anwar AE, Bui MM, Ahmed AA. CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. Int J Exp Pathol 2015;96:81-6. [PMID: 25670065 DOI: 10.1111/iep.12115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Kowalski JP, Pelletier RD, McDonald MG, Kelly EJ, Rettie AE. Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H- benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1: β-oxidation as a potential augmenting pathway for inhibition. Xenobiotica 2021;51:901-15. [PMID: 33993844 DOI: 10.1080/00498254.2021.1930281] [Reference Citation Analysis]
3 Guo Z, Johnson V, Barrera J, Porras M, Hinojosa D, Hernández I, Mcgarrah P, Potter DA. Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev 2018;37:409-23. [DOI: 10.1007/s10555-018-9749-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Qixing M, Juqing X, Yajing W, Gaochao D, Wenjie X, Run S, Anpeng W, Lin X, Feng J, Jun W. The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma. Tumour Biol 2017;39:1010428317698340. [PMID: 28381170 DOI: 10.1177/1010428317698340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H, Wang C, Wang X, Yang G, Cai X, Falck JR, Yang J. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol 2012;264:73-83. [PMID: 22841774 DOI: 10.1016/j.taap.2012.07.019] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
6 O'Dwyer D, Ralton LD, O'Shea A, Murray GI. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One. 2011;6:e27718. [PMID: 22125622 DOI: 10.1371/journal.pone.0027718] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
7 Heys SD, Stewart KN, McKenzie EJ, Miller ID, Wong SY, Sellar G, Rees AJ. Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res Treat 2012;135:539-48. [PMID: 22886449 DOI: 10.1007/s10549-012-2190-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
8 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 21.2] [Reference Citation Analysis]
9 Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. Int J Cancer 2016;138:758-69. [PMID: 26297509 DOI: 10.1002/ijc.29812] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
10 Kawahara B, Faull KF, Janzen C, Mascharak PK. Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. J Med Chem 2021;64:8437-46. [PMID: 34097831 DOI: 10.1021/acs.jmedchem.1c00404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Shadboorestan A, Tarfiei GA, Montazeri H, Sepand MR, Zangooei M, Khedri A, Ostad SN, Ghahremani MH. Invasion and migration of MDA-MB-231 cells are inhibited by block of AhR and NFAT: role of AhR/NFAT1/β4 integrin signaling: inhibition of invasion and migration by the block of AhR and NFAT. J Appl Toxicol 2019;39:375-84. [DOI: 10.1002/jat.3728] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kowalski JP, Mcdonald MG, Pelletier RD, Hanenberg H, Wiek C, Rettie AE. Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1. J Med Chem 2020;63:4824-36. [DOI: 10.1021/acs.jmedchem.0c00101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC. EET signaling in cancer. Cancer Metastasis Rev. 2011;30:525-540. [PMID: 22009066 DOI: 10.1007/s10555-011-9315-y] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 7.8] [Reference Citation Analysis]
14 Li J, Zhang Q, Chen Z, Xu D, Wang Y. A network-based pathway-extending approach using DNA methylation and gene expression data to identify altered pathways. Sci Rep 2019;9:11853. [PMID: 31413306 DOI: 10.1038/s41598-019-48372-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Al-Saraireh YM, Alboaisa NS, Alrawashdeh HM, Hamdan O, Al-Sarayreh S, Al-Shuneigat JM, Nofal MN. Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. Ecancermedicalscience 2020;14:1114. [PMID: 33144882 DOI: 10.3332/ecancer.2020.1114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Licznerska B, Baer-Dubowska W. What might the presence of 'orphan' CYP450 isoforms in breast epithelial cells mean for the future of targeted therapeutics? Expert Opin Drug Metab Toxicol 2021;17:135-7. [PMID: 33112688 DOI: 10.1080/17425255.2021.1844182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Lin JT, Chan TC, Li CF, Huan SKH, Tian YF, Liang PI, Pan CT, Shiue YL. Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. APMIS 2019;127:170-80. [PMID: 30803053 DOI: 10.1111/apm.12939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Rodriguez-Ruiz ME, Buqué A, Hensler M, Chen J, Bloy N, Petroni G, Sato A, Yamazaki T, Fucikova J, Galluzzi L. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology 2019;8:e1655964. [PMID: 31646105 DOI: 10.1080/2162402X.2019.1655964] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 15.3] [Reference Citation Analysis]
19 Johnson AL, Edson KZ, Totah RA, Rettie AE. Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer. Adv Pharmacol 2015;74:223-62. [PMID: 26233909 DOI: 10.1016/bs.apha.2015.05.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
20 Brown GT, Cash BG, Blihoghe D, Johansson P, Alnabulsi A, Murray GI. The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer. PLoS One 2014;9:e90776. [PMID: 24608339 DOI: 10.1371/journal.pone.0090776] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
21 Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V, Trnková M, Kodet R, Mrhalová M, Kubáčková K, Gatěk J, Vážan P, Souček P. The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients. Medicine (Baltimore) 2014;93:e255. [PMID: 25526449 DOI: 10.1097/MD.0000000000000255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
22 Osborne N, Leahy C, Lee YK, Rote P, Song BJ, Hardwick JP. CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD). Biochem Pharmacol 2021;:114841. [PMID: 34798124 DOI: 10.1016/j.bcp.2021.114841] [Reference Citation Analysis]
23 Sharma S, Liu J, Zhang X, Sharma SS, Sorensen EJ, Bureik M. New luciferin-based probe substrates for human CYP26A1. Biochem Biophys Rep 2020;24:100861. [PMID: 33294638 DOI: 10.1016/j.bbrep.2020.100861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Jiao X, Liu R, Huang J, Lu L, Li Z, Xu L, Li E. Cellular Retinoic-Acid Binding Protein 2 in Solid Tumor. Curr Protein Pept Sci 2020;21:507-16. [PMID: 32013828 DOI: 10.2174/1389203721666200203150721] [Reference Citation Analysis]
25 Kumbhar PS, Diwate SK, Mali UG, Shinde TU, Disouza JI, Manjappa AS. Development and validation of RP-HPLC method for simultaneous estimation of docetaxel and ritonavir in PLGA nanoparticles. Ann Pharm Fr 2020;78:398-407. [PMID: 32681903 DOI: 10.1016/j.pharma.2020.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Luo B, Yan D, Yan H, Yuan J. Cytochrome P450: Implications for human breast cancer. Oncol Lett 2021;22:548. [PMID: 34093769 DOI: 10.3892/ol.2021.12809] [Reference Citation Analysis]
27 Li X, Cai Y. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients. Aging (Albany NY) 2020;12:16457-75. [PMID: 32858528 DOI: 10.18632/aging.103734] [Reference Citation Analysis]
28 Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T. Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. Pharmacol Ther 2015;150:109-28. [PMID: 25603423 DOI: 10.1016/j.pharmthera.2015.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
29 Eun HS, Cho SY, Lee BS, Kim S, Song IS, Chun K, Oh CH, Yeo MK, Kim SH, Kim KH. Cytochrome P450 4A11 expression in tumor cells: A favorable prognostic factor for hepatocellular carcinoma patients. J Gastroenterol Hepatol 2019;34:224-33. [PMID: 30069903 DOI: 10.1111/jgh.14406] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
30 Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Sarayreh S, Almuhaisen GH, Alnawaiseh N, Al Shuneigat JM, Alrawashdeh HM. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep 2021;11:5581. [PMID: 33692504 DOI: 10.1038/s41598-021-85188-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Bebenek IG, Solaimani P, Bui P, Hankinson O. CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett 2012;209:30-4. [PMID: 22155357 DOI: 10.1016/j.toxlet.2011.11.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
32 Sharma R, Williams IS, Gatchie L, Sonawane VR, Chaudhuri B, Bharate SB. Furanoflavones pongapin and lanceolatin B blocks the cell cycle and induce senescence in CYP1A1-overexpressing breast cancer cells. Bioorg Med Chem 2018;26:6076-86. [PMID: 30448188 DOI: 10.1016/j.bmc.2018.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Wei X, Zhang D, Dou X, Niu N, Huang W, Bai J, Zhang G. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer 2014;14:841. [PMID: 25406731 DOI: 10.1186/1471-2407-14-841] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
34 Eun HS, Cho SY, Lee BS, Seong IO, Kim KH. Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma. Mol Med Rep 2018;18:4865-76. [PMID: 30280198 DOI: 10.3892/mmr.2018.9526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
35 Yan Q, Machalz D, Zöllner A, Sorensen EJ, Wolber G, Bureik M. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast. Biochem Pharmacol 2017;146:174-87. [PMID: 28951277 DOI: 10.1016/j.bcp.2017.09.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
36 Lolodi O, Wang YM, Wright WC, Chen T. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. Curr Drug Metab 2017;18:1095-105. [PMID: 28558634 DOI: 10.2174/1389200218666170531112038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
37 Kharkwal H, Batool F, Koentgen F, Bell DR, Kendall DA, Ebling FJP, Duce IR. Generation and phenotypic characterisation of a cytochrome P450 4x1 knockout mouse. PLoS One 2017;12:e0187959. [PMID: 29227996 DOI: 10.1371/journal.pone.0187959] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA. Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. Cell Chem Biol 2017;24:1259-1275.e6. [PMID: 28919040 DOI: 10.1016/j.chembiol.2017.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
39 Khayeka-Wandabwa C, Ma X, Jia Y, Bureik M. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer. Immunobiology 2022;227:152174. [PMID: 34999392 DOI: 10.1016/j.imbio.2021.152174] [Reference Citation Analysis]
40 Machalz D, Li H, Du W, Sharma S, Liu S, Bureik M, Wolber G. Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor. Eur J Med Chem 2021;215:113255. [PMID: 33611185 DOI: 10.1016/j.ejmech.2021.113255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Sneha S, Baker SC, Green A, Storr S, Aiyappa R, Martin S, Pors K. Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. Biomedicines 2021;9:290. [PMID: 33809117 DOI: 10.3390/biomedicines9030290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
42 Thuy Phuong NT, Kim JW, Kim JA, Jeon JS, Lee JY, Xu WJ, Yang JW, Kim SK, Kang KW. Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer. Oncotarget 2017;8:71054-69. [PMID: 29050342 DOI: 10.18632/oncotarget.20329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
43 Zhang G, Kodani S, Hammock BD. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res 2014;53:108-23. [PMID: 24345640 DOI: 10.1016/j.plipres.2013.11.003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 10.9] [Reference Citation Analysis]
44 Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Sarayra YM, Al-Saraireh RA, Al-Muhaisen GH, Al-Mahdy YS, Al-Kharabsheh AM, Abufraijeh SM, Alrawashdeh HM. Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer. Curr Oncol 2021;28:3573-84. [PMID: 34590601 DOI: 10.3390/curroncol28050306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
45 Evangelista EA, Cho CW, Aliwarga T, Totah RA. Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors. Front Pharmacol 2020;11:828. [PMID: 32581794 DOI: 10.3389/fphar.2020.00828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Zhang Y, Yuan Z, Shen R, Jiang Y, Xu W, Gu M, Gu X. Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer. Oncol Lett 2020;20:290. [PMID: 33029206 DOI: 10.3892/ol.2020.12153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Singh RD, Patel KA, Patel JB, Pandya SJ, Patel PS. Evidence of Association of CYP1A1 Expression in Blood Lymphocytes and Clinicopathological Variables in Oral Cancer. Ind J Clin Biochem 2022;37:178-84. [DOI: 10.1007/s12291-021-00958-1] [Reference Citation Analysis]
48 Rodriguez M, Potter DA. CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res 2013;11:780-92. [PMID: 23576571 DOI: 10.1158/1541-7786.MCR-12-0675] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 5.1] [Reference Citation Analysis]
49 Zhang R, Huang M, Wang H, Wu S, Yao J, Ge Y, Lu Y, Hu Q. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion. Pathol Oncol Res 2021;27:597527. [PMID: 34257549 DOI: 10.3389/pore.2021.597527] [Reference Citation Analysis]
50 Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi R, Zhao F. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med 2015;35:340-8. [PMID: 25516145 DOI: 10.3892/ijmm.2014.2041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
51 Khayeka-Wandabwa C, Ma X, Cao X, Nunna V, Pathak JL, Bernhardt R, Cai P, Bureik M. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. Int Immunopharmacol 2019;73:64-71. [PMID: 31082724 DOI: 10.1016/j.intimp.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
52 Nakano M, Lockhart CM, Kelly EJ, Rettie AE. Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. Drug Metab Rev 2014;46:247-60. [PMID: 24856391 DOI: 10.3109/03602532.2014.921190] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
53 Kaluzhskiy L, Ershov P, Yablokov E, Shkel T, Grabovec I, Mezentsev Y, Gnedenko O, Usanov S, Shabunya P, Fatykhava S, Popov A, Artyukov A, Styshova O, Gilep A, Strushkevich N, Ivanov A. Human Lanosterol 14-Alpha Demethylase (CYP51A1) Is a Putative Target for Natural Flavonoid Luteolin 7,3'-Disulfate. Molecules 2021;26:2237. [PMID: 33924405 DOI: 10.3390/molecules26082237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Hu J, Frömel T, Fleming I. Angiogenesis and vascular stability in eicosanoids and cancer. Cancer Metastasis Rev 2018;37:425-38. [PMID: 29808461 DOI: 10.1007/s10555-018-9732-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
55 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
56 Valencia-Cervantes J, Huerta-Yepez S, Aquino-Jarquín G, Rodríguez-Enríquez S, Martínez-Fong D, Arias-Montaño JA, Dávila-Borja VM. Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1α‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation. Oncol Rep 2019;41:178-90. [PMID: 30320358 DOI: 10.3892/or.2018.6790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Ingelman-sundberg M, Lauschke VM. Can CYP Inhibition Overcome Chemotherapy Resistance? Trends in Pharmacological Sciences 2020;41:503-6. [DOI: 10.1016/j.tips.2020.05.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
58 Szaefer H, Licznerska B, Cykowiak M, Baer-Dubowska W. Expression of CYP2S1 and CYP2W1 in breast cancer epithelial cells and modulation of their expression by synthetic methoxy stilbenes. Pharmacol Rep 2019;71:1001-5. [PMID: 31561186 DOI: 10.1016/j.pharep.2019.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Parks AJ, Pollastri MP, Hahn ME, Stanford EA, Novikov O, Franks DG, Haigh SE, Narasimhan S, Ashton TD, Hopper TG, Kozakov D, Beglov D, Vajda S, Schlezinger JJ, Sherr DH. In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol 2014;86:593-608. [PMID: 25159092 DOI: 10.1124/mol.114.093369] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
60 Sensorn I, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med 2013;6:93-8. [PMID: 24019753 DOI: 10.2147/PGPM.S44006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
61 Ducassou L, Jonasson G, Dhers L, Pietrancosta N, Ramassamy B, Xu-li Y, Loriot M, Beaune P, Bertho G, Lombard M, Mansuy D, André F, Boucher J. Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies. Biochimica et Biophysica Acta (BBA) - General Subjects 2015;1850:1426-37. [DOI: 10.1016/j.bbagen.2015.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
62 Kim S, Kim JM, Lee HJ, Lim JS, Seong IO, Kim KH. Alteration of CYP4A11 expression in renal cell carcinoma: diagnostic and prognostic implications. J Cancer 2020;11:1478-85. [PMID: 32047554 DOI: 10.7150/jca.36438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Zheng L, Li X, Meng X, Chou J, Hu J, Zhang F, Zhang Z, Xing Y, Liu Y, Xi T. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer. Mol Cell Endocrinol 2016;427:133-42. [PMID: 26980484 DOI: 10.1016/j.mce.2016.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
64 Hlaváč V, Václavíková R, Brynychová V, Ostašov P, Koževnikovová R, Kopečková K, Vrána D, Gatěk J, Souček P. Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response. Int J Mol Sci 2021;22:2826. [PMID: 33802237 DOI: 10.3390/ijms22062826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Khayeka-Wandabwa C, Zhao J, Pathak JL, Wu H, Bureik M. Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1. Breast Cancer Res Treat 2021. [PMID: 34725776 DOI: 10.1007/s10549-021-06435-w] [Reference Citation Analysis]
66 Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem 2011;286:17543-59. [PMID: 21402692 DOI: 10.1074/jbc.M110.198515] [Cited by in Crossref: 66] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
67 Dhers L, Ducassou L, Boucher JL, Mansuy D. Cytochrome P450 2U1, a very peculiar member of the human P450s family. Cell Mol Life Sci 2017;74:1859-69. [PMID: 28083596 DOI: 10.1007/s00018-016-2443-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
68 Torres-Zárate C, Vences-Mejía A, Espinosa-Aguirre JJ, Díaz-Díaz E, Palacios-Acosta JM, Cárdenas-Cardós R, Hernández-Arrazola D, Shalkow-Klincovstein J, Jurado RR, Santes-Palacios R, Molina-Ortiz D. Expression of Cytochrome P450 Enzymes in Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Possible Role in Carcinogenesis and Treatment Response. Int J Toxicol 2022;:10915818221085909. [PMID: 35437033 DOI: 10.1177/10915818221085909] [Reference Citation Analysis]
69 Lourenço FC, Munro J, Brown J, Cordero J, Stefanatos R, Strathdee K, Orange C, Feller SM, Sansom OJ, Vidal M, Murray GI, Olson MF. Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut 2014;63:480-93. [PMID: 23585469 DOI: 10.1136/gutjnl-2012-303883] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
70 Liu X, Huang X, Zhang S, Niu F, Ouyang Y, Shou Z, Liu J. Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population. Int J Clin Oncol 2019;24:179-88. [PMID: 30218411 DOI: 10.1007/s10147-018-1346-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Chavez Alvarez AC, Zarifi Khosroshahi M, Côté M, Gagné-boulet M, Fortin S. 4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells. Bioorganic & Medicinal Chemistry 2018;26:5045-52. [DOI: 10.1016/j.bmc.2018.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Frömel T, Naeem Z, Pirzeh L, Fleming I. Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology. Pharmacol Ther 2021;:108049. [PMID: 34848204 DOI: 10.1016/j.pharmthera.2021.108049] [Reference Citation Analysis]
73 Li Y, Steppi A, Zhou Y, Mao F, Miller PC, He MM, Zhao T, Sun Q, Zhang J. Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. Sci Rep 2017;7:4747. [PMID: 28684774 DOI: 10.1038/s41598-017-04250-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
74 Rajagopal T, Seshachalam A, Rathnam KK, Jothi A, Talluri S, Venkatabalasubramanian S, Dunna NR. Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women. Breast Cancer Res Treat 2021;186:823-37. [PMID: 33392841 DOI: 10.1007/s10549-020-06028-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Tarawneh F, Al-Sarayreh S, Almuhaisen GH, Satari AO, Al-Shuneigat J, Alrawashdeh HM. Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers. Breast Cancer (Dove Med Press) 2021;13:565-74. [PMID: 34675653 DOI: 10.2147/BCTT.S329770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wang C, Li Y, Chen H, Huang K, Liu X, Qiu M, Liu Y, Yang Y, Yang J. CYP4X1 Inhibition by Flavonoid CH625 Normalizes Glioma Vasculature through Reprogramming TAMs via CB2 and EGFR-STAT3 Axis. J Pharmacol Exp Ther 2018;365:72-83. [PMID: 29437915 DOI: 10.1124/jpet.117.247130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
77 Go R, Hwang K, Kim C, Byun Y, Nam K, Choi K. Effect of dioxin and 17β-estradiol on the expression of cytochrome P450 1A1 gene via an estrogen receptor dependent pathway in cellular and xenografted models: GO et al. Environmental Toxicology 2017;32:2225-33. [DOI: 10.1002/tox.22438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
78 Li Y, Zhao H, Wang Y, Zheng H, Yu W, Chai H, Zhang J, Falck JR, Guo AM, Yue J, Peng R, Yang J. Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicology and Applied Pharmacology 2013;272:37-48. [DOI: 10.1016/j.taap.2013.05.031] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
79 Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 2013;110:6530-5. [PMID: 23553837 DOI: 10.1073/pnas.1304321110] [Cited by in Crossref: 201] [Cited by in F6Publishing: 190] [Article Influence: 22.3] [Reference Citation Analysis]
80 Mitsui Y, Chang I, Kato T, Hashimoto Y, Yamamura S, Fukuhara S, Wong DK, Shiina M, Imai-Sumida M, Majid S, Saini S, Shiina H, Nakajima K, Deng G, Dahiya R, Tanaka Y. Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer. Oncotarget 2016;7:49107-21. [PMID: 27203547 DOI: 10.18632/oncotarget.9470] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
81 Bai X, Chen Y, Hou X, Huang M, Jin J. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev 2016;48:541-67. [PMID: 27320238 DOI: 10.1080/03602532.2016.1197239] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]
82 van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol. 2019;84:487-499. [PMID: 31309254 DOI: 10.1007/s00280-019-03905-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
83 Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Sarayreh S, Almuhaisen GH, Alnawaiseh N, Al-Shuneigat JM, Alrawashdeh HM. Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients. Onco Targets Ther 2021;14:5249-60. [PMID: 34803385 DOI: 10.2147/OTT.S332037] [Reference Citation Analysis]
84 Dhers L, Pietrancosta N, Ducassou L, Ramassamy B, Dairou J, Jaouen M, André F, Mansuy D, Boucher J. Spectral and 3D model studies of the interaction of orphan human cytochrome P450 2U1 with substrates and ligands. Biochimica et Biophysica Acta (BBA) - General Subjects 2017;1861:3144-53. [DOI: 10.1016/j.bbagen.2016.07.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
85 Luo B, Chen C, Wu X, Yan D, Chen F, Yu X, Yuan J. Cytochrome P450 2U1 Is a Novel Independent Prognostic Biomarker in Breast Cancer Patients. Front Oncol 2020;10:1379. [PMID: 32850442 DOI: 10.3389/fonc.2020.01379] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Arellano-gutiérrez CV, Quintas-granados LI, Cortés H, González del Carmen M, Leyva-gómez G, Bustamante-montes LP, Rodríguez-morales M, López-reyes I, Padilla-mendoza JR, Rodríguez-páez L, Figueroa-gonzález G, Reyes-hernández OD. Indole-3-Carbinol, a Phytochemical Aryl Hydrocarbon Receptor-Ligand, Induces the mRNA Overexpression of UBE2L3 and Cell Proliferation Arrest. CIMB 2022;44:2054-68. [DOI: 10.3390/cimb44050139] [Reference Citation Analysis]
87 Alnabulsi A, Swan R, Cash B, Alnabulsi A, Murray GI. The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance. Br J Cancer 2017;116:1612-20. [PMID: 28557975 DOI: 10.1038/bjc.2017.135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
88 Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19:2057-2070. [PMID: 30139042 DOI: 10.22034/apjcp.2018.19.8.2057] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
89 Fekry MI, Xiao Y, Berg JZ, Guengerich FP. A Role for the Orphan Human Cytochrome P450 2S1 in Polyunsaturated Fatty Acid ω-1 Hydroxylation Using an Untargeted Metabolomic Approach. Drug Metab Dispos 2019;47:1325-32. [PMID: 31511258 DOI: 10.1124/dmd.119.089086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
90 Ghaffari H, Petzold LR. Identification of influential proteins in the classical retinoic acid signaling pathway. Theor Biol Med Model 2018;15:16. [PMID: 30322383 DOI: 10.1186/s12976-018-0088-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
91 Fortin S, Charest-Morin X, Turcotte V, Lauvaux C, Lacroix J, Côté MF, Gobeil S, C-Gaudreault R. Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells. J Med Chem 2017;60:4963-82. [PMID: 28535350 DOI: 10.1021/acs.jmedchem.7b00343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
92 Madanayake TW, Lindquist IE, Devitt NP, Mudge J, Rowland AM. A transcriptomic approach to elucidate the physiological significance of human cytochrome P450 2S1 in bronchial epithelial cells. BMC Genomics 2013;14:833. [PMID: 24279958 DOI: 10.1186/1471-2164-14-833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
93 Madanayake TW, Fidler TP, Fresquez TM, Bajaj N, Rowland AM. Cytochrome P450 2S1 depletion enhances cell proliferation and migration in bronchial epithelial cells, in part, through modulation of prostaglandin E(2) synthesis. Drug Metab Dispos 2012;40:2119-25. [PMID: 22863683 DOI: 10.1124/dmd.112.046466] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
94 Sausville LN, Williams SM, Pozzi A. Cytochrome P450 epoxygenases and cancer: A genetic and a molecular perspective. Pharmacology & Therapeutics 2019;196:183-94. [DOI: 10.1016/j.pharmthera.2018.11.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]